1100001H23Rik Inhibitors
Chemical inhibitors of the protein 1100001H23Rik can play a significant role in modulating its activity through various mechanisms. Staurosporine, a well-known kinase inhibitor, can broadly inhibit protein kinases that may be responsible for the phosphorylation of 1100001H23Rik, thus preventing its activation. Similarly, rapamycin, an mTOR inhibitor, can inhibit downstream kinases in the mTOR signaling pathway, which could be crucial for the activation state of 1100001H23Rik. LY294002, which targets PI3K, can inhibit this kinase, leading to a cascade effect that can prevent the activation of 1100001H23Rik if PI3K signaling is required for its function. U0126, a MEK inhibitor, can block the MAPK/ERK pathway and, consequently, can inhibit the activation of 1100001H23Rik if it relies on this particular pathway for its activity.
Further, the p38 MAPK inhibitor SB203580 can inhibit the activation of 1100001H23Rik by obstructing p38 MAPK-mediated phosphorylation events. SP600125, which inhibits JNK, can prevent JNK-mediated phosphorylation that may be necessary for the activation of 1100001H23Rik. Inhibition by PP2, a Src family kinase inhibitor, can lead to the inactivity of 1100001H23Rik if Src kinases are involved in its phosphorylation. Furthermore, BAY 11-7082 can inhibit the activation of NF-κB, and if 1100001H23Rik is regulated by NF-κB or involved in related signaling pathways, this inhibitor can suppress its activity. Dasatinib, which inhibits Src family kinases and BCR-ABL tyrosine kinase, can also prevent the phosphorylation and activation of 1100001H23Rik if these kinases regulate it. Gefitinib, an EGFR tyrosine kinase inhibitor, can block the EGFR signaling that might be essential for the activation of 1100001H23Rik. PD98059, another MEK inhibitor, can stop the MAPK/ERK signaling, thereby inhibiting the activity of 1100001H23Rik if it is dependent on this pathway. Lastly, wortmannin, a PI3K inhibitor like LY294002, can inhibit any PI3K-dependent activation process of 1100001H23Rik, blocking the protein's activity through this pathway. Each of these inhibitors can interact with their respective targets, directly or indirectly altering the phosphorylation status and functional activity of the protein 1100001H23Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad spectrum of protein kinases, which could include kinases that phosphorylate 1100001H23Rik, leading to its functional inhibition by preventing necessary phosphorylation events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is pivotal in regulating cell growth and protein synthesis. Inhibition of mTOR could lead to the functional inhibition of 1100001H23Rik by blocking the activity of kinases that are downstream of mTOR signaling and that are responsible for the activation of 1100001H23Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. By inhibiting PI3K, it could lead to functional inhibition of 1100001H23Rik if the protein's activity is dependent on PI3K signaling, as this would prevent the activation of downstream kinases that are required for 1100001H23Rik activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, a kinase that acts in the MAPK/ERK pathway. The inhibition of MEK could result in the functional inhibition of 1100001H23Rik if the protein requires MAPK/ERK signaling for its activity, as this would prevent necessary phosphorylation by ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK could lead to functional inhibition of 1100001H23Rik if p38 MAPK is involved in phosphorylating and activating 1100001H23Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, and this could inhibit 1100001H23Rik by preventing activation via JNK-mediated phosphorylation if JNK is involved in the signaling pathways that regulate the activity of 1100001H23Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. If Src kinases are involved in the activation or regulation of 1100001H23Rik, then inhibition by PP2 could lead to functional inhibition of 1100001H23Rik through lack of necessary phosphorylation events. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation. If 1100001H23Rik is regulated by NF-κB or is part of a pathway involving NF-κB signaling, BAY 11-7082 could inhibit the functional activity of 1100001H23Rik by blocking NF-κB-dependent signaling events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase and BCR-ABL tyrosine kinase inhibitor. It could functionally inhibit 1100001H23Rik by inhibiting the kinases that phosphorylate and activate 1100001H23Rik, assuming Src or BCR-ABL kinases play a role in its regulation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits EGFR tyrosine kinase, which could lead to functional inhibition of 1100001H23Rik if EGFR signaling is necessary for the activation or regulation of 1100001H23Rik, by blocking the phosphorylation events that activate 1100001H23Rik. | ||||||